Anti-CLL1-CD33-NKG2D bicephali CAR-T

· Xuzhou Medical University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-CLL1-CD33-NKG2D bicephali CAR-T, covering 2026-01-27 to 2026-01-27. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

See pricing